HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (Nasdaq-Global Market:IMMC), which is developing and commercializing proprietary cell and molecular-based human diagnostic and life-science research products with an initial focus on cancer, today announced its results of operations for the three months ended March 31, 2007.
